Is monthly retreatment with intravitreal bevacizumab (Avastin®) necessary in neovascular age-related macular degeneration?
Purpose To report our short-term experience with bevacizumab in neovascular age-related macular degeneration (AMD) and recommend a new treatment strategy. Methods Retrospective chart review of 29 consecutive patients receiving 1.25 mg of intravitreal bevacizumab for AMD and completing 12 weeks of fo...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , |
| Format: | article |
| Published: |
2010
|
| Online Access: | http://hdl.handle.net/10725/10823 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861937/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|